ALLEVIATE Trial - A Phase 3 Trial in Subjects With Allergic Conjunctivitis

See also
Status	Clinical Trial	Phase
Completed	`NCT03660878` - A Methodology Development Environmental Clinical Trial of Reproxalap in Subjects With Seasonal Allergic Conjunctivitis	Phase 1/Phase 2
Completed	`NCT03682965` - Texan Allergy & Sinus Center Mountain Cedar Intra-Lymphatic Immunotherapy Study	Phase 2
Completed	`NCT01685242` - A Single-Center,Evaluation of the Onset and Duration of Action of AC-170 0.24% Compared to Vehicle	Phase 3
Completed	`NCT01697969` - Confocal Analysis of Corneal Structures of Symptomatic Allergic Conjunctivitis Patients	Phase 4
Completed	`NCT01439815` - An Allergen BioCube (ABC) Study Evaluating the Efficacy of Fluticasone Propionate Nasal Spray Compared to Placebo	Phase 4
Completed	`NCT01294969` - Patient Perception Study for AL-4943A	Phase 4
Completed	`NCT01471184` - The Effects of Ectoin® Allergy Nasal Spray and Ectoin® Allergy Eye Drops Compared to Placebo	Phase 1
Completed	`NCT00609128` - Effect of Olopatadine on Allergic Tear Mediators	N/A
Recruiting	`NCT05969236` - A Study of MDI-1228_mesylate Ophthalmic Solution in Healthy Adults	Phase 1
Active, not recruiting	`NCT04619017` - Airway Immune Response to Allergens (Use Lay Language Here)	Phase 1
Not yet recruiting	`NCT01012752` - A Multicenter Study to Evaluate Safety and Efficacy of Specific Immunotherapy With Modified Allergen Extracts	Phase 3
Completed	`NCT01698814` - A Six-Week Safety Study of an Investigational Ophthalmic Solution	Phase 3
Completed	`NCT01754766` - AGN-229666 for the Treatment of Allergic Conjunctivitis	Phase 2
Completed	`NCT01443442` - Bepreve vs. Alrex in Subjects With Moderate to Severe Allergic Conjunctivitis	Phase 4
Completed	`NCT01203540` - Evaluation of the Effect and Tolerance of Preservative Free NAAGA on the Inflammatory Component and Symptoms of Dry Eye Syndrome in Allergic Conjunctivitis Patients	Phase 4
Completed	`NCT00987272` - Study of Olopatadine HCl Ophthalmic Solutions Compared to Vehicle Using the Conjunctival Allergen Challenge (CAC) Model of Acute Allergic Conjunctivitis in Japanese Subjects	Phase 3
Completed	`NCT00769886` - Ketotifen/Naphazoline Ophthalmic Solution in the Conjunctival Allergen Challenge Model of Allergic Conjunctivitis.	Phase 3
Completed	`NCT00569777` - Safety Study of a Contact Lens With Ketotifen in Healthy, Normal Volunteers	Phase 3
Completed	`NCT00586664` - Efficacy and Safety Study of Bepotastine Besilate Ophthalmic Solution in Allergic Conjunctivitis	Phase 3
Completed	`NCT00534794` - Study of Two Marketed Ocular Anti-Allergy Medications in Subjects With Allergic Conjunctivitis	Phase 4

NCT number	NCT03494504
Study type	Interventional
Source	Aldeyra Therapeutics, Inc.
Contact
Status	Completed
Phase	Phase 3
Start date	March 30, 2018
Completion date	November 5, 2018

ALLEVIATE Trial - A Phase 3 Trial in Subjects With Allergic Conjunctivitis

Clinical Trial Summary

Clinical Trial Description

Study Design

Related Conditions & MeSH terms